A Phase 2 interventional study of Biological: mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-30.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 15th largest by enrollment, is one of 4 that started in 2020, is one of 7 in phase 2, and was the 2nd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 13th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2020, is one of 5 in phase 2, and was the 1st registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
This is a 3-part Phase 2a study, with Part A (Blinded Phase), Part B (Open-label Interventional Phase), and Part C (Rollover Proof of Concept).
Participants in Part A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part B of the study is designed to offer participants to be unblinded so that participants who received placebo in Part A can request 2 doses of open-label mRNA-1273 vaccine. Additionally, participants who originally received 1 or 2 doses of mRNA-1273 (50 microgram [μg] or 100 μg vaccine) during Part A, will have the opportunity to request to receive a single booster dose of mRNA-1273.
Part C will be a proof-of-concept rollover study to evaluate a vaccine to treat mutations of SARS-CoV2, such as the S-protein of the B.1.351 variant. Part C will include approximately 60 participants, who are currently enrolled in Moderna's Phase 3 mRNA-1273-P301 study (NCT04470427), have already been unblinded, and have previously received 2 doses of mRNA-1273 at least 6 months earlier. At enrollment into Part C of this study, their participation in mRNA-1273-P301 study will be terminated. Part C will evaluate the safety and immunogenicity of 2 dose levels (20 µg and 50 µg) of mRNA-1273.351 and mRNA-1273/mRNA-1273.351 mixture (50 µg total), given as a single booster dose.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 660 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Each participant must meet all of the following criteria during the screening period and at Day 1, unless noted otherwise, to be enrolled in this study:
Female participants of may be enrolled in the study if the participant fulfills all the following criteria:
Adequate female contraception is defined as consistent and correct use of a Food and Drug Administration (FDA) approved contraceptive method in accordance with the product label. For example:
Adequate contraception for male participants is defined as:
Additional Key Inclusion Criteria for Part C
Key Exclusion Criteria:
Participants meeting any of the following criteria at the Screening Visit (Day 0) or at Day 1, unless noted otherwise, will be excluded from the study:
Additional Key Exclusion Criteria for Part C
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants aged 18-54 years will receive 1 intramuscular (IM) injection of 50 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 18-54 years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.
Biological: Biological: mRNA-1273
Part A: Participants aged 55+ years will receive 1 IM injection of 50 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received 50 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.
Biological: Biological: mRNA-1273
Part A: Participants aged 18-54 years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 18-54 years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.
Biological: Biological: mRNA-1273
Part A: Participants aged 55+ years will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received 100 ug mRNA-1273 during Part A, will receive 1 IM injection of mRNA-1273 (booster dose) on Day 1.
Biological: Biological: mRNA-1273
Part A: Participants aged 18-54 years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29. Part B: Participants aged 18-54 who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.
Biological: Biological: mRNA-1273 · Biological: Placebo
Part A: Participants aged 55+ years will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29. Part B: Participants aged 55+ years who choose to be unblinded and received mRNA-1273-matching placebo during Part A, will receive 1 IM injection of 100 ug mRNA-1273 on Day 1 and Day 29.
Biological: Biological: mRNA-1273 · Biological: Placebo
Part C: Participants will receive 1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1.
Biological: mRNA-1273.351
Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA 1273.351 on Day 1.
Biological: mRNA-1273.351
Part C: Participants will receive 1 IM booster dose of 50 ug of mRNA-1273/mRNA-1273.351 mixture on Day 1.
Biological: Biological: mRNA-1273 · Biological: mRNA-1273.351
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Sterile liquid for injection
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 7 days post-vaccination
Number of Participants With Unsolicited AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to 28 days post-vaccination
Number of Participants With Medically-Attended Adverse Events (MAAEs)
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to Month 15
Number of Participants With SAEs
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to Month 15
Part A: Level of Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2)-Specific Binding Antibody (bAb) as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.
Time frame: Days 1 (Baseline), 29, 43, 57, and 209
Part B: Level of SARS-CoV-2-Specific bAb as Measured by ELISA
The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
Time frame: Days 1 (Baseline) and 29
Part C: Level of SARS-CoV-2-Specific bAb as Measured by MSD
The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.
Time frame: Days 1 (Baseline), 8, 15, and 29
Part A: Titer of SARS-CoV-2-Specific Neutralizing Antibody (nAb)
The GM titer (microneutralization \[MN\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.
Time frame: Days 1 (Baseline), 29, 43, 57, and 209
Part B: Titer of SARS-CoV-2-Specific nAb
The GM titer (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
Time frame: Days 1 (Baseline), 29, and 181
Part C: Titer of SARS-CoV-2-Specific nAb
The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.
Time frame: Days 1 (Baseline), 8, 15, 29, and 181
Part A: Percentage of Participants With Seroconversion From Baseline
Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.
Time frame: Days 29, 43, and 57
Part B: Percentage of Participants With Seroconversion From Baseline
Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \<LLOQ replaced by 0.5\*LLOQ. Values \>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
Time frame: Days 29 and 181
Part C: Percentage of Participants With Seroconversion From Baseline
Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values \>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.
Time frame: Days 8, 15, 29, and 181
Participants in Part A were blinded to study treatment. After completion of Part A, participants could have chosen to be unblinded and to participate in Part B (open-label). Participants in Part C (proof-of-concept rollover) were unblinded and had received 2 doses of mRNA-1273 in Study mRNA-1273-P301 (Study P301; NCT04470427).
| Milestone | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Started | 200 | 200 | 200 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug during part a | 200 | 200 | 200 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 188 | 185 | 182 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 15 | 18 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 6 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 3 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent (covid-19 non-infection related) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent (other) | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 173 | 171 | 158 | 0 | 0 | 0 |
| Received at least 1 dose of study drug during part b | 0 | 0 | 0 | 173 | 171 | 158 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 161 | 166 | 152 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 12 | 5 | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 6 | 1 | 4 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 6 | 3 | 2 | 0 | 0 | 0 |
| Milestone | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 20 | 20 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 18 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal of consent (other) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 95 | 69 | 72 | 65 | 73 | 50 | 13 | 10 | 12 |
| Grade 2 | 61 | 90 | 21 | 59 | 59 | 71 | 6 | 2 | 3 |
| Grade 3 | 25 | 32 | 6 | 29 | 18 | 28 | 0 | 2 | 2 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Month 15), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 57 | 56 | 51 | 17 | 25 | 42 | 3 | 3 | 4 |
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Medically-Attended Adverse Events (MAAEs) | 74 | 38 | 64 | 42 | 47 | 59 | 7 | 3 | 7 |
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With SAEs | 5 | 2 | 0 | 2 | 2 | 2 | 0 | 1 | 0 |
The geometric mean (GM) level of VAC58 spike immunoglobulin G (IgG) antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 1 and ULOQ was 2052. The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.
| arbitrary units per mL (AU/mL) | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo |
|---|---|---|---|
| Day 1 (Baseline) | 0.70 (0.63 to 0.78) | 0.67 (0.60 to 0.73) | 0.67 (0.61 to 0.73) |
| Day 29 | 59.42 (52.05 to 67.82) | 81.51 (70.19 to 94.67) | 0.68 (0.61 to 0.76) |
| Day 43 | 720.85 (660.30 to 786.96) | 834.66 (765.28 to 910.33) | 0.65 (0.59 to 0.71) |
| Day 57 | 519.48 (474.00 to 569.33) | 647.22 (588.98 to 711.21) | 0.67 (0.60 to 0.75) |
| Day 209 | 97.02 (87.58 to 107.47) | 128.00 (114.44 to 143.18) | 0.91 (0.73 to 1.14) |
The GM level of VAC65 spike IgG antibodies, as measured by ELISA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 1 and ULOQ was 2052. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
| AU/mL | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 |
|---|---|---|
| Day 1 (Baseline) | 86.29 (76.89 to 96.83) | 109.56 (96.79 to 124.02) |
| Day 29 | 1069.73 (992.92 to 1152.49) | 1083.21 (1018.75 to 1151.75) |
The GM titer (microneutralization \[MN\] and MN50) of serum nAb against SARS-CoV-2 as measured by live virus MN assays is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280 at Days 1 (Baseline), 29, 43, and 57. For MN50, LLOQ was 91.10 and ULOQ was 2031.87 at Days 1 (Baseline), 29, 43, and 57. For MN, LLOQ was 160 and ULOQ was 1280 at Day 209. For MN50, LLOQ was 318.46 and ULOQ was 1917.83 at Day 209. The 95% CI was calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM titer, then back transformed to the original scale for presentation.
| titers | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo |
|---|---|---|---|
| MN, Day 1 (Baseline) | 20.6 (20.0 to 21.2) | 20.6 (19.7 to 21.5) | 20.8 (20.1 to 21.4) |
| MN, Day 29 | 112.2 (94.9 to 132.7) | 149.6 (127.3 to 175.9) | 21.9 (20.5 to 23.5) |
| MN, Day 43 | 1145.4 (1101.3 to 1191.1) | 1185.8 (1142.9 to 1230.3) | 21.2 (20.1 to 22.4) |
| MN, Day 57 | 1090.6 (1038.9 to 1144.9) | 1095.5 (1041.5 to 1152.2) | 21.8 (20.4 to 23.4) |
| MN, Day 209 | 254.4 (219.4 to 294.9) | 354.8 (309.2 to 407.2) | 85.3 (80.6 to 90.2) |
| MN50, Day 1 (Baseline) | 46.500 (45.425 to 47.600) | 46.684 (44.957 to 48.477) | 47.109 (45.745 to 48.512) |
| MN50, Day 29 | 173.750 (148.550 to 203.225) | 227.433 (194.207 to 266.343) | 49.231 (46.355 to 52.285) |
| MN50, Day 43 | 1761.660 (1690.216 to 1836.124) | 1813.480 (1741.280 to 1888.673) | 48.059 (45.820 to 50.408) |
| MN50, Day 57 | 1632.442 (1550.245 to 1718.998) | 1656.064 (1570.464 to 1746.330) | 49.141 (46.267 to 52.194) |
| MN50, Day 209 | 401.508 (350.667 to 459.720) | 538.798 (472.772 to 614.045) | 167.002 (159.249 to 175.133) |
The GM titer (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 18.5 and ULOQ was 45118 for IC50. LLOQ was 14.3 and ULOQ was 10232 for ID80. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. The PP Set included participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
| titers | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 |
|---|---|---|
| ID50, Day 1 (Baseline) | 104.658 (88.282 to 124.070) | 150.224 (125.726 to 179.495) |
| ID50, Day 29 | 1834.309 (1600.233 to 2102.623) | 1951.735 (1729.606 to 2202.392) |
| ID50, Day 181 | 915.331 (622.504 to 1345.904) | 673.273 (578.167 to 784.025) |
| ID80, Day 1 (Baseline) | 39.646 (33.789 to 46.518) | 55.686 (47.459 to 65.341) |
| ID80, Day 29 | 696.085 (609.203 to 795.358) | 736.617 (661.040 to 820.835) |
| ID80, Day 181 | 291.791 (203.597 to 418.189) | 228.635 (197.044 to 265.291) |
The GM titer (ID50, ID80) of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. For NAb ID50 Titers, LLOQ was 18.5 and ULOQ was 45118. For NAb ID80 Titers, LLOQ was 14.3 and ULOQ was 10232. For NAb ID50 Titers against B.1.351, LLOQ was 19.5 and ULOQ was 385.7. For NAb ID80 Titers against B.1.351, LLOQ was 12.5 and ULOQ was 102.2. The 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation.
| titers | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|
| ID50 Against Original Strain, Day 1 (Baseline) | 196.107 (133.338 to 288.424) | 156.011 (80.546 to 302.180) | 79.572 (53.625 to 118.074) |
| ID50 Against Original Strain, Day 8 | 1089.901 (748.146 to 1587.770) | 1568.894 (1030.722 to 2388.062) | 1183.096 (900.313 to 1554.700) |
| ID50 Against Original Strain, Day 15 | 2221.382 (1434.353 to 3440.255) | 1725.415 (1212.131 to 2456.053) | 3082.946 (1891.502 to 5024.874) |
| ID50 Against Original Strain, Day 29 | 1808.133 (1323.211 to 2470.767) | 1757.179 (1117.782 to 2762.324) | 3691.896 (2330.908 to 5847.548) |
| ID50 Against Original Strain, Day 181 | — | 512.129 (303.261 to 864.853) | — |
| ID80 Against Original Strain, Day 1 (Baseline) | 76.279 (53.035 to 109.712) | 56.344 (33.804 to 93.911) | 30.774 (21.565 to 43.915) |
| ID80 Against Original Strain, Day 8 | 448.109 (300.430 to 668.381) | 500.158 (341.180 to 733.214) | 458.435 (351.348 to 598.161) |
| ID80 Against Original Strain, Day 15 | 730.018 (509.454 to 1046.073) | 678.926 (462.561 to 996.498) | 947.774 (647.781 to 1386.696) |
| ID80 Against Original Strain, Day 29 | 632.263 (460.549 to 868.001) | 615.967 (397.103 to 955.460) | 1156.267 (743.617 to 1797.907) |
| ID80 Against Original Strain, Day 181 | — | 182.837 (108.300 to 308.673) | — |
| ID50 Against B.1.351, Day 1 (Baseline) | 45.574 (28.832 to 72.036) | 32.026 (19.758 to 51.911) | 18.338 (13.572 to 24.776) |
| ID50 Against B.1.351, Day 8 | 919.281 (592.738 to 1425.720) | 1088.511 (670.315 to 1767.610) | 706.141 (456.010 to 1093.475) |
| ID50 Against B.1.351, Day 15 | 1088.432 (736.353 to 1608.854) | 1113.392 (652.885 to 1898.716) | 1166.830 (760.230 to 1790.895) |
| ID50 Against B.1.351, Day 29 | 1537.029 (1066.352 to 2215.458) | 1116.885 (714.119 to 1746.813) | 1129.955 (742.454 to 1719.699) |
| ID50 Against B.1.351, Day 181 | — | 141.773 (76.471 to 262.839) | — |
| ID80 Against B.1.351, Day 1 (Baseline) | 17.403 (10.870 to 27.863) | 15.046 (10.088 to 22.442) | 8.326 (6.727 to 10.306) |
| ID80 Against B.1.351, Day 8 | 289.360 (196.260 to 426.626) | 313.644 (203.582 to 483.210) | 225.475 (160.419 to 316.915) |
| ID80 Against B.1.351, Day 15 | 435.078 (300.742 to 629.418) | 371.579 (228.889 to 603.223) | 413.424 (284.856 to 600.020) |
| ID80 Against B.1.351, Day 29 | 486.398 (341.630 to 692.511) | 345.827 (214.472 to 557.633) | 362.540 (249.138 to 527.560) |
| ID80 Against B.1.351, Day 181 | — | 55.887 (29.969 to 104.220) | — |
Based on MN titers and MN50 titers of serum nAb against SARS-CoV-2 as measured by live virus MN assays, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using the Clopper-Pearson method at each post-baseline timepoint. Seroconversion at a participant level was defined as a change of nAb titer from below the limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ. For MN, LLOQ was 40 and ULOQ was 1280. For MN50, LLOQ was 91.10 and ULOQ was 2031.87.
| percentage of participants | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo |
|---|---|---|---|
| MN Titer, Day 29 | 78.0 (70.9 to 84.0) | 88.9 (83.4 to 93.1) | 1.7 (0.3 to 4.8) |
| MN Titer, Day 43 | 100 (97.4 to 100.0) | 100 (97.6 to 100.0) | 0.6 (0.0 to 3.1) |
| MN Titer, Day 57 | 100 (97.6 to 100.0) | 100 (97.6 to 100.0) | 1.8 (0.4 to 5.0) |
| MN50 Titer, Day 29 | 65.5 (57.8 to 72.6) | 76.7 (69.8 to 82.6) | 1.1 (0.1 to 4.0) |
| MN50 Titer, Day 43 | 100 (97.4 to 100.0) | 100 (97.6 to 100.0) | 0.6 (0.0 to 3.1) |
| MN50 Titer, Day 57 | 100 (97.6 to 100.0) | 100 (97.6 to 100.0) | 1.8 (0.4 to 5.0) |
Based on ID50 and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay, % of participants with seroconversion from baseline reported with 2-sided 95% CI using Clopper-Pearson method at each postbaseline timepoint. Seroconversion at participant level defined as change of nAb titer from below LOD or LLOQ to equal to or above LOD or LLOQ (respectively) or 4-times or higher titer ratio in participants with preexisting nAb titers. Antibody values \<LLOQ replaced by 0.5\*LLOQ. Values \>ULOQ converted to ULOQ. LLOQ: 18.5 and ULOQ: 45118 for IC50. LLOQ: 14.3 and ULOQ: 10232 for ID80. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation. PP Set: participants with a study injection, required baseline data, had postinjection results at timepoint of primary interest for immunogenicity analysis, no major protocol deviations impacting immune response, and didn't have SARS-CoV-2.
| percentage of participants | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 |
|---|---|---|
| ID50, Day 29 | 92.4 (86.8 to 96.2) | 87.9 (81.6 to 92.7) |
| ID50, Day 181 | 81.6 (65.7 to 92.3) | 54.4 (46.0 to 62.6) |
| ID80, Day 29 | 95.2 (90.3 to 98.0) | 93.3 (88.0 to 96.7) |
| ID80, Day 181 | 78.9 (62.7 to 90.4) | 53.7 (45.3 to 62.0) |
Based on ID50 titers and ID80 titers of nAb against SARS-CoV-2 pseudotyped viruses (original strain and beta variant \[B.1.351\]) as measured by pseudovirus nAb assay, percentage of participants with seroconversion from baseline are reported with 2-sided 95% CI using Clopper-Pearson method at each post-baseline timepoint. Seroconversion at participant level defined as a change of nAb titer from below LOD or LLOQ ≥LOD or LLOQ (respectively), or a 4-times or higher titer ratio in participants with pre-existing nAb titers. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values \>ULOQ were converted to ULOQ. NAb ID50 Titers: LLOQ was 18.5 and ULOQ was 45118. NAb ID80 Titers: LLOQ was 14.3 and ULOQ was 10232. NAb ID50 Titers against B.1.351: LLOQ was 19.5 and ULOQ was 385.7. NAb ID80 Titers against B.1.351: LLOQ was 12.5 and ULOQ was 102.2. 95% CI calculated based on t-distribution of log-transformed values for GMT, then back transformed to original scale for presentation.
| percentage of participants | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|
| ID50 Against Original Strain, Day 8 | 47.4 (24.4 to 71.1) | 78.9 (54.4 to 93.9) | 100 (83.2 to 100.0) |
| ID50 Against Original Strain, Day 15 | 78.9 (54.4 to 93.9) | 90.0 (68.3 to 98.8) | 95.0 (75.1 to 99.9) |
| ID50 Against Original Strain, Day 29 | 84.2 (60.4 to 96.6) | 95.0 (75.1 to 99.9) | 100 (83.2 to 100.0) |
| ID50 Against Original Strain, Day 181 | — | 38.9 (17.3 to 64.3) | — |
| ID80 Against Original Strain, Day 8 | 68.4 (43.4 to 87.4) | 84.2 (60.4 to 96.6) | 95.0 (75.1 to 99.9) |
| ID80 Against Original Strain, Day 15 | 84.2 (60.4 to 96.6) | 95.0 (75.1 to 99.9) | 100 (83.2 to 100.0) |
| ID80 Against Original Strain, Day 29 | 84.2 (60.4 to 96.6) | 95.0 (75.1 to 99.9) | 95.0 (75.1 to 99.9) |
| ID80 Against Original Strain, Day 181 | — | 38.9 (17.3 to 64.3) | — |
| ID50 Against B.1.351, Day 8 | 100 (82.4 to 100.0) | 100 (82.4 to 100.0) | 100 (83.2 to 100.0) |
| ID50 Against B.1.351, Day 15 | 94.7 (74.0 to 99.9) | 100 (83.2 to 100.0) | 100 (83.2 to 100.0) |
| ID50 Against B.1.351, Day 29 | 100 (82.4 to 100.0) | 100 (83.2 to 100.0) | 100 (83.2 to 100.0) |
| ID50 Against B.1.351, Day 181 | — | 61.1 (35.7 to 82.7) | — |
| ID80 Against B.1.351, Day 8 | 94.7 (74.0 to 99.9) | 94.7 (74.0 to 99.9) | 100 (83.2 to 100.0) |
| ID80 Against B.1.351, Day 15 | 94.7 (74.0 to 99.9) | 100 (83.2 to 100.0) | 100 (83.2 to 100.0) |
| ID80 Against B.1.351, Day 29 | 100 (82.4 to 100.0) | 100 (83.2 to 100.0) | 100 (83.2 to 100.0) |
| ID80 Against B.1.351, Day 181 | — | 55.6 (30.8 to 78.5) | — |
The GM level of SARS-CoV-2 protein antibody against B.1.351, as measured by MSD MULTIPLEX is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ are converted to the ULOQ. LLOQ was 18 and ULOQ was 4200000. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, respectively, then back transformed to the original scale for presentation.
| AU/mL | Part C: 20 ug mRNA-1273.351 | 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|
| Day 1 (Baseline) | 59742.3 (43057.8 to 82891.8) | 44921.5 (28539.6 to 70706.5) | 33409.8 (25264.8 to 44180.6) |
| Day 8 | 240180.0 (166361.1 to 346754.3) | 267002.2 (199939.9 to 356558.2) | 228572.0 (178986.7 to 291894.2) |
| Day 15 | 297880.2 (224089.6 to 395969.4) | 418215.3 (311988.7 to 560610.2) | 384521.1 (282461.4 to 523457.3) |
| Day 29 | 297962.7 (227337.5 to 390528.5) | 345765.9 (251640.5 to 475098.5) | 367714.1 (268913.2 to 502815.1) |
Collected over Up to Month 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 50 ug mRNA-1273 | 0/200 (0%) | 5/200 (2.5%) | 105/200 (52.5%) |
| Part A: 100 ug mRNA-1273 | 0/200 (0%) | 2/200 (1%) | 76/200 (38%) |
| Part A: Placebo | 0/200 (0%) | 0/200 (0%) | 94/200 (47%) |
| Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | 0/173 (0%) | 2/173 (1.2%) | 51/173 (29.5%) |
| Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | 0/171 (0%) | 2/171 (1.2%) | 62/171 (36.3%) |
| Part B: Placebo Then 100 ug mRNA-1273 | 0/158 (0%) | 2/158 (1.3%) | 70/158 (44.3%) |
| Part C: 20 ug mRNA-1273.351 | 0/20 (0%) | 0/20 (0%) | 8/20 (40%) |
| Part C: 50 ug mRNA-1273.351 | 0/20 (0%) | 1/20 (5%) | 4/20 (20%) |
| Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture | 0/20 (0%) | 0/20 (0%) | 9/20 (45%) |
| Event | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic carcinoma stage IVInfections and infestations | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 0/158 | 0/20 | 1/20 | 0/20 |
| BradycardiaCardiac disorders | 1/200 | 0/200 | 0/200 | 0/173 | 0/171 | 1/158 | 0/20 | 0/20 | 0/20 |
| SepsisInfections and infestations | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 1/158 | 0/20 | 0/20 | 0/20 |
| Atrioventricular block completeCardiac disorders | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 1/158 | 0/20 | 0/20 | 0/20 |
| Peptic ulcer perforationGastrointestinal disorders | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 1/158 | 0/20 | 0/20 | 0/20 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/200 | 0/200 | 0/200 | 0/173 | 1/171 | 0/158 | 0/20 | 0/20 | 0/20 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/200 | 0/200 | 0/200 | 0/173 | 1/171 | 0/158 | 0/20 | 0/20 | 0/20 |
| PericarditisCardiac disorders | 0/200 | 0/200 | 0/200 | 1/173 | 0/171 | 0/158 | 0/20 | 0/20 | 0/20 |
| Deep vein thrombosisVascular disorders | 0/200 | 0/200 | 0/200 | 1/173 | 0/171 | 0/158 | 0/20 | 0/20 | 0/20 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/200 | 0/200 | 0/200 | 1/173 | 0/171 | 0/158 | 0/20 | 0/20 | 0/20 |
| Event | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part B: 50 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: 100 ug mRNA-1273 Then 50 ug mRNA-1273 | Part B: Placebo Then 100 ug mRNA-1273 | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture |
|---|---|---|---|---|---|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 6/200 | 2/200 | 3/200 | 0/173 | 4/171 | 2/158 | 0/20 | 1/20 | 3/20 |
| COVID-19Infections and infestations | 3/200 | 2/200 | 26/200 | 9/173 | 8/171 | 16/158 | 0/20 | 0/20 | 0/20 |
| DepressionPsychiatric disorders | 3/200 | 4/200 | 2/200 | 0/173 | 0/171 | 0/158 | 2/20 | 0/20 | 1/20 |
| HypertensionVascular disorders | 5/200 | 1/200 | 0/200 | 2/173 | 0/171 | 2/158 | 0/20 | 2/20 | 2/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/200 | 4/200 | 4/200 | 1/173 | 2/171 | 2/158 | 0/20 | 1/20 | 2/20 |
| Pharyngitis streptococcalInfections and infestations | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 0/158 | 2/20 | 0/20 | 0/20 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/200 | 0/200 | 0/200 | 0/173 | 0/171 | 0/158 | 0/20 | 0/20 | 2/20 |
| HeadacheNervous system disorders | 16/200 | 9/200 | 8/200 | 3/173 | 8/171 | 1/158 | 0/20 | 0/20 | 1/20 |
| FatigueGeneral disorders | 16/200 | 5/200 | 7/200 | 1/173 | 7/171 | 5/158 | 0/20 | 1/20 | 1/20 |
| Urinary tract infectionInfections and infestations | 3/200 | 2/200 | 3/200 | 0/173 | 2/171 | 2/158 | 1/20 | 0/20 | 0/20 |
Safety Set: All participants who received any study injection in their respective part of the study. Note, participants who received placebo in Part A, received 100 ug mRNA-1273 in Part B (N=158). Participants who received 50 or 100 ug mRNA-1273 in Part A, received 50 ug mRNA-1273 in Part B (N=344). Since Baseline Characteristics data for participants in Part B are included in Part A, separate columns are not reported here for Part B.
| Age, Customized(Participants) | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture | Total |
|---|---|---|---|---|---|---|---|
| Between 18 and 55 years | 100 | 100 | 100 | 13 | 9 | 9 | 331 |
| >=55 years | 100 | 100 | 100 | 7 | 11 | 11 | 329 |
| Sex: Female, Male(Participants) | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture | Total |
|---|---|---|---|---|---|---|---|
| Female | 137 | 124 | 129 | 15 | 9 | 8 | 422 |
| Male | 63 | 76 | 71 | 5 | 11 | 12 | 238 |
| Ethnicity (NIH/OMB)(Participants) | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 16 | 16 | 1 | 0 | 1 | 49 |
| Not Hispanic or Latino | 184 | 184 | 184 | 19 | 20 | 19 | 610 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Part A: 50 ug mRNA-1273 | Part A: 100 ug mRNA-1273 | Part A: Placebo | Part C: 20 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273.351 | Part C: 50 ug mRNA-1273/mRNA-1273.351 Mixture | Total |
|---|---|---|---|---|---|---|---|
| White | 188 | 188 | 193 | 20 | 19 | 19 | 627 |
| Black or African American | 5 | 8 | 3 | 0 | 0 | 0 | 16 |
| Asian | 2 | 2 | 3 | 0 | 1 | 0 | 8 |
| American Indian or Alaska Native | 2 | 1 | 0 | 0 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Multiracial | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Other | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2020 to primary completion in Oct 2021, 16 months.
Results were first posted in Dec 2022, 1 year 2 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 16 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273